| scholarly article | Q13442814 |
| P2093 | author name string | R Moreau | |
| A Gadano | |||
| D Lebrec | |||
| M Clozel | |||
| Y Calmus | |||
| P Sogni | |||
| S Cailmail | |||
| A Gomola | |||
| P2860 | cites work | 200 years of digitalis: the emerging central role of the sodium ion in the control of cardiac force | Q38154778 |
| Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells | Q39418552 | ||
| Cirrhotic cardiomyopathy: getting to the heart of the matter | Q41021596 | ||
| Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome | Q41100847 | ||
| 17 beta-Estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line | Q41475091 | ||
| Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats | Q41970443 | ||
| The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver | Q42458498 | ||
| Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance | Q46185466 | ||
| Plasma endothelin levels in patients with cirrhosis and their relationships to the severity of cirrhosis and renal function | Q46270575 | ||
| Effect of vasodilators on hepatic microcirculation in cirrhosis: a study in the isolated perfused rat liver. | Q54352341 | ||
| The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo | Q64446819 | ||
| Venous smooth muscle contains vasoconstrictor ETB-like receptors | Q67487748 | ||
| Effects of endothelin in portal hypertensive rats | Q67504194 | ||
| Circulating levels of endothelin in cirrhosis | Q70681124 | ||
| Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats | Q71073515 | ||
| Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis | Q71650207 | ||
| Bosentan improves renal regional blood flow in rats with experimental congestive heart failure | Q71711499 | ||
| Plasma endothelin-1 and -3 in cirrhosis: relationship with systemic hemodynamics, renal function and neurohumoral systems | Q71757368 | ||
| Functional role of endothelin ETA and ETB receptors in venous and arterial smooth muscle | Q71965006 | ||
| Elevated circulating plasma endothelin-1 concentrations in cirrhosis | Q72756391 | ||
| Clinical significance of plasma endothelin-1 in patients with chronic liver disease | Q72894416 | ||
| Endothelin-1 induces liver vasoconstriction through both ETA and ETB receptors | Q73423873 | ||
| Endothelin-induced vasoconstriction in isolated perfused liver preparations from normal and cirrhotic rats | Q73441846 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hemodynamics | Q1642137 |
| P304 | page(s) | 655-659 | |
| P577 | publication date | 1998-09-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. | |
| P478 | volume | 28 |
| Q73745092 | 48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study |
| Q44041359 | Accelerated reversal of carbon tetrachloride-induced cirrhosis in rats by the endothelin receptor antagonist TAK-044. |
| Q54104969 | Bacterial infection in the pathogenesis of variceal bleeding. |
| Q37959188 | Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation |
| Q43613012 | Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/reperfusion injury |
| Q34342983 | Cirrhosis of the liver and receptor-mediated function in vascular smooth muscle |
| Q55322529 | Comparison of Two Protocols of Carbon Tetrachloride-Induced Cirrhosis in Rats - Improving Yield and Reproducibility. |
| Q44071046 | Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan |
| Q35068040 | Current management of portal hypertension |
| Q46244181 | Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: experimental study in Wistar rats |
| Q43994820 | Effects of endothelins on hepatic stellate cell synthesis of endothelin-1 during hepatic wound healing |
| Q43201099 | Effects of transmitters and interleukin-10 on rat hepatic fibrosis induced by CCl4. |
| Q34342993 | Endothelial dysfunction in cirrhosis and portal hypertension |
| Q30488861 | Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease |
| Q48057773 | Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats. |
| Q35768938 | Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. |
| Q54085349 | Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. |
| Q74194209 | Endothelin-1 plays a major role in portal hypertension of biliary cirrhotic rats through endothelin receptor subtype B together with subtype A in vivo |
| Q56925258 | Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis |
| Q34559070 | Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension |
| Q44002506 | Impact of dopamine and endothelin-1 antagonism on portal venous blood flow during laparoscopic surgery |
| Q54782119 | Increased expression of endothelin receptors in human cirrhosis--relationship with splanchnic hemodynamics. |
| Q80988416 | Management of portal hypertension |
| Q73444656 | Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance |
| Q39148718 | Molecular pathophysiology of portal hypertension. |
| Q40097867 | Ovarian hormones modulate endothelin A and B receptor expression |
| Q32043307 | Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure |
| Q57003194 | Plasma endothelin-1 levels in patients with biliary atresia: possible role in development of portal hypertension |
| Q52969695 | Regulation of the hepatic endothelin system in advanced biliary fibrosis in rats. |
| Q36132271 | Role of endothelin in fibrosis and anti-fibrotic potential of bosentan |
| Q36564609 | Role of endothelin in systemic and portal resistance in cirrhosis |
| Q44216609 | Role of thromboxane A2 in early BDL-induced portal hypertension |
| Q34024754 | Stellate cells and the "reversible component" of portal hypertension |
| Q24685743 | Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats |
| Q73582179 | The endothelin antagonist bosentan does not improve survival in severe experimental pancreatitis in rats |
| Q34240085 | The role of endothelin in the pathogenesis of Chagas' disease |
| Q90660734 | Treatment Barriers in Portopulmonary Hypertension |
| Q73246074 | Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats |
| Q36141427 | Variceal bleeding: pharmacological therapy. |
| Q73838465 | Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy |
| Q80221005 | [Functional component of portal hypertension] |
Search more.